Publication date: Jan 16, 2025
Using a test-negative design, we modeled the association between receipt of BNT162b2 KP.2 vaccine and symptomatic COVID-19 among adults testing for SARS-CoV-2 at walk-in clinics in a large US retail pharmacy chain (9/5/2024-12/8/2024). At a median of 37 days post-vaccination, those who received BNT162b2 KP.2 were 48% less likely to test positive.
Concepts | Keywords |
---|---|
Employees | Adults |
Flu | Bnt162b2 |
Mph1 | Cov |
Polymerase | Covid |
Cvs | |
Days | |
Kp | |
Medrxiv | |
Pfizer | |
Preprint | |
Received | |
Sars | |
Test | |
Vaccine | |
Years |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
drug | DRUGBANK | Coenzyme M |
disease | IDO | history |
disease | IDO | symptom |
drug | DRUGBANK | Methionine |
disease | MESH | chronic condition |
disease | IDO | susceptibility |
disease | MESH | Infectious Diseases |
Download Document
(Visited 2 times, 1 visits today)